Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis

Circulation

Volumn 106, Issue 22, 2002, Pages 2842-2847

  Lanza, Gregory M ^a,c   Yu, Xin ^a   Winter, Patrick M ^a   Abendschein, Dana R ^a   Karukstis, Kerry K ^b   Scott, Michael J ^a   Chinen, Lori K ^a   Fuhrhop, Ralph W ^a   Scherrer, David E ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVEY MUDD COLLEGE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Drugs; Magnetic resonance imaging; Restenosis

Indexed keywords

CONTRAST MEDIUM; DOXORUBICIN; NANOPARTICLE; PACLITAXEL;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOSIMETRY; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; HEART VENTRICLE REMODELING; HYDROPHOBICITY; INTIMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RESTENOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL COUNT; CELL DIVISION; CELL MEMBRANE; CELLS, CULTURED; CONTRAST MEDIA; CORONARY RESTENOSIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUORINE COMPOUNDS; FLUOROCARBONS; GADOLINIUM DTPA; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE, SMOOTH, VASCULAR; OLEIC ACID; OLEIC ACIDS; PACLITAXEL; PARTICLE SIZE; SWINE; THROMBOPLASTIN;

EID: 0037180413     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000044020.27990.32     Document Type: Article

References (28)

1. Reidy MA. A reassessment of endothelial injury and arterial lesion formation. Lab Invest. 1985;53:513-520.
2. Clowes AW, Clowes MM, Fingerle J, et al. Kinetics of cellular proliferation after arterial injury: V. Role of acute distension in the induction of smooth muscle proliferation. Lab Invest. 1989;60:360-364.
3. Lincoff A, Furst J, Ellis S, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997;29:808-816.
4. Strecker E, Gabelmann A, Boos I, et al. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc Intervent Radiol. 1998;21:487-496.
5. Liu M, Anderson P, Luo J, et al. Local delivery of ethanol inhibits intimal hyperplasia in pig coronary arteries after balloon injury. Circulation. 1997;96:2295-2301.
6. Axel D, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645.
7. Kalinowski M, Tepe G, Schieber A, et al. Local administration of ramiprilat is less effective than oral ramipril in preventing restenosis after balloon angioplasty in an animal model. J Vasc Interv Radiol. 1999;10:1397-1404.
8. Nozawa Y, Matsuura N, Miyake H, et al. Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci. 1999;64:2061-2067.
9. Oberhoff M, Herdeg C, Baumbach A, et al. Time course of smooth muscle cell proliferation after local drug delivery of low-molecular-weight heparin using a porous balloon catheter. Cathet Cardiovasc Diagn. 1997;41:268-274.
10. Song C, Labhasetwar V, Cui X, et al. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Controlled Release. 1998;54:201-211.
11. Suh H, Jeong B, Rathi R, et al. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J Biomed Mater Res. 1998;42:331-338.
12. Valero F, Hamon M, Fournier C, et al. Intramural injection of biodegradable microspheres as a local drug-delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty. J Cardiovasc Pharmacol. 1998;31:513-519.
13. Sousa JE. Sustained suppression of neointimal proliferation by sirolimuseluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
14. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
15. Rensing BJ. Coronary restenosis elimination with a sirolimus eluting stent: First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001;22:2125-2130.
16. Lanza GM, Abendschein DR, Hall CH, et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echo. 2000;13:608-614.
17. Lanza G, Abendschein D, Hall C, et al. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. Invest Radiol. 2000;35:227-234.
18. Lanza G, Wallace K, Scott M, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996;94:3334-3340.
19. Trissel LA, Xu QA, Gilbert DL. Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion Solutions. Ann Pharmacother. 1998;32:1013-1016.
20. Alvarez-Cedron L, Sayalero M, Lanao J. High-performance liquid chromatography validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B. 1999;721:271-278.
21. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000;44:433-439.
22. Yu X, Song S-K, Chen J, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med.;2000;44:867-872.
23. Flacke S, Fischer S, Scott M, et al. A novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285.
24. Hernandez-Borrell J, Mas F, Puy J. A theoretical approach to describe monolayer-liposome lipid interaction. Biophys Chem. 1990;36:47-55.
25. Jahnig F. Lipid exchange between membranes. Biophys J. 1984;46:687-694.
26. Wimley W, Thompson T. Phosphatidylethanolamine enhances the concentration-dependent exchange of phospholipids between bilayers. Biochemistry. 1991;30:4200-4204.
27. Jones J, Thompson T. Spontaneous phosphatidylcholine transfer by collision between vesicles at high lipid concentration. Biochemistry. 1989;28:129-134.
28. Baumbach A, Herdeg C, Kluge M, et al. Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Cathet Cardiovasc Intervent. 1999;47:102-106.